

PRESS RELEASE  
14 January 2022 15:15:00 CET



## ProstaLund signs distribution agreement for the UK market

**ProstaLund AB has signed an exclusive distribution agreement with the British company iUrology.**

In line with the stated strategy, after acquiring a substantial base in its home market, ProstaLund is now starting its internationalization outside the Nordic region with an initial agreement regarding a collaboration with the British company iUrology.

ProstaLund's product CoreFlow® - Soft Stent has been particularly interesting in view of the current pandemic as it can be used both for patients waiting for BPE surgery and in patients with acute urinary retention. In the evaluation and discussions with the English urologists, the entire portfolio has been presented and there is obviously a curiosity also for heat treatment with CoreTherm as well as for the Schelin catheter as a stand-alone product for local anesthesia of the prostate prior to BPH procedures other than CoreTherm.

Shakeel Osman, CEO iUrology, comments: "We have evaluated ProstaLund's products during the fall 2021. The dialogues we have had with urologists in England have been very positive and we see that ProstaLund's portfolio is of interest to the UK market. In the short-term Covid-19 bothers us, but we have high hopes as soon as the restrictions are eased."

"This agreement is important for the future. It is unlikely that it will have a significant impact to our sales in 2022, but it gives us a good basis for the next few years.", says CEO Johan Wennerholm.

**For further information, please contact:**

---

Johan Wennerholm, CEO  
Tel. +46 (0) 730 429997  
Email: [johan.wennerholm@prostalund.com](mailto:johan.wennerholm@prostalund.com)



PRESS RELEASE  
14 January 2022 15:15:00 CET

## About ProstaLund

---

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

### **Certified Adviser:**

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: [ca@vhcorp.se](mailto:ca@vhcorp.se)

## Attachments

---

ProstaLund signs distribution agreement for the UK market